| Nov 14 |
XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia…
|
| Nov 14 |
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
|
| Nov 14 |
X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ...
|
| Nov 14 |
X4 Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Nov 14 |
X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript
|
| Nov 13 |
X4 Pharmaceuticals: Q3 Earnings Snapshot
|
| Nov 13 |
X4 Pharmaceuticals GAAP EPS of -$0.18 misses by $0.01, revenue of $0.56M misses by $1.13M
|
| Nov 13 |
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 13 |
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
|
| Nov 13 |
Earnings Scheduled For November 13, 2024
|
